Book a Meeting

Non-Fucosylated Anti-Human GPVI (9O12. 2) Therapeutic Antibody (CAT#: BioBet-942ZP) Datasheet

Target
GPVI
Isotype
IgG
Description
ADCC-Enhanced anti-GPVI (9O12.2 ) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Thrombosis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced GPVI antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GP6
Full Name
glycoprotein VI (platelet)
Background
This gene encodes a platelet membrane glycoprotein of the immunoglobulin superfamily. The encoded protein is a receptor for collagen and plays a critical role in collagen-induced platelet aggregation and thrombus formation. The encoded protein forms a complex with the Fc receptor gamma-chain that initiates the platelet activation signaling cascade upon collagen binding. Mutations in this gene are a cause of platelet-type bleeding disorder-11 (BDPLT11). Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Alternative Names
GP6; glycoprotein VI (platelet); GPIV; GPVI; BDPLT11; platelet glycoprotein VI; glycoprotein 6; platelet collagen receptor
Gene ID
51206
UniProt ID
Q9UK05
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with GP6 include Bleeding Disorder, Platelet-Type, 11 and Sticky Platelet Syndrome.
Related Pathways
Its related pathways are Platelet Aggregation Inhibitor Pathway, Pharmacodynamics and Cell surface interactions at the vascular wall.
Function
Collagen receptors are involved in collagen-induced platelet adhesion and activation. It plays a key role in platelet procoagulant activity and subsequent formation of thrombin and fibrin. This procoagulant function may contribute to the formation of arterial and venous thrombosis. The signal pathway involves the FcR-ma chain, Src kinase (may be FYN or LYN) and SYK (adapter protein LAT), leading to the activation of PLCG2.
Post-translational modifications
1.N-linked glycosylation at Asn-92 is not required for the cell surface expression, but contributes to maximal adhesion to type I collagen, collagen-related peptide (CRP), and, to a lesser extent, to the snake venom C-type lectin convulxin (CVX). 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn92
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
9O12. 2
Host
Humanized
Species Reactivity
Human
Description
This is a single chain variable fragment directed against human glycoprotein VI, used for treatment of thrombosis.
Indication
Thrombosis

Thrombosis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany